Drug name

Pharmacologic action

Company

Indication

Development phase

Cymbalta (duloxetine)

5HT/NE reuptake inhib.

Eli Lilly

Dep/Anx

NDA submitted

Estorra (eszopiclone)

GABA-A modulator

Sepracor

Insomnia

NDA submitted

Variza (gepirone)

5HT1a partial agonist

Organon

Dep/Anx

NDA submitted

Pregabalin

Voltage-gated Ca+ alpha(2)delta subunit modulator

Pfizer

Anxiety/Pain/Bipolar/Epilepsy

NDA expected 4Q03

Indiplon

GABA-A modulator (at BZ1 sites)

Pfizer/Neurocrine/

DOV Pharm.

Insomnia

NDA expected 1Q04

Aprepitant

NK-1 antagonist

Merck

Dep/Anx

Phase III

Zolpidem MR

GABA-A agonist

Sanofi

Insomnia

Phase III

Deramaciclane

5HT2 antagonist

Pfizer

Anxiety

Phase III

EmSam

(transdermal selegiline)

MAO-inhibitor

Somerset

Depression

Phase III

LAX-101

"purified" EPA

Amarin

Huntington's/Dep

Phase III

Agomelatine

5-HT2C antagonist, 5-HT2B antagonist, melatonin receptor agonist

Servier

Dep/Anx

Phase III

Pagoclone

GABA-A modulator

Indevus

Anxiety

Phase III

SR 58611

beta-3-adrenergic agonist

Sanofi-Synthelabo

Depression

Phase III

Bicifadine

5HT/NE reuptake inhib., NMDA antagonism

DOV Pharmaceuticals

Pain

Phase III

Ocinaplon

GABA-A agonist

DOV Pharmaceuticals

Anxiety

Phase III

Gaboxadol

GABA-A agonist

Lundbeck

Insomnia

Phase III

ORG 34517

GR antagonist

Organon

Depression

Phase III

Lesopitron

5HT1a partial agonist

Esteve, Inc.

Anxiety

Phase III

Nemifitide (INN 00835)

Peptide ligand (injectable)

Innapharma

Depression

Phase II/III

LY354740

mGluR2, mGluR3 agonist

Eli Lilly

Anxiety

Phase II

ORG 24448

AMPA modulator

Organon/Cortex

Schizophrenia/Dep

Phase II

GW597599

NK-2 antagonist

GSK

Dep/Anx

Phase II

SR 48968

NK-1 antagonist

Sanofi

Dep/Anx

Phase II/ Disco?

CP-122,721

NK-1 antagonist

Pfizer

Dep/Anx

Phase II

R-673

NK-1 antagonist

Roche

Dep/Anx

Phase II

TAK-637

NK-1 antagonist

Takeda/Abbott

Dep/Anx

Phase II

(R)-sibutramine metabolite

DA/NE reuptake inhib.

Sepracor

ADHD/Dep

Phase II

SEP174559

GABA-A (alpha2 subtype) agonist, nicotinic acetylcholine antagonist, NMDA antagonist

Sepracor

Anxiety

Phase II

NAD-299 (robalzotan)

5HT1a antagonist

AstraZeneca

Dep/Ax

Phase II

Milnacipran

NE/5HT reuptake inhib.

Cypress

Dep/FMS

Phase II

CX717, other AMPAkine compounds

AMPA modulators

Cortex/Organon

MCI/Alzheimer's

Phase II

SL 65.1498

GABA-A agonist

Sanofi-Synthelabo

Anxiety/Muscular contractions

Phase II

Eplivanserin (SR 46349)

5HT2 antagonist

Sanofi-Synthelabo

Insomnia

Phase II

Saredutant (SR 48968)

NK-2 antagonist

Sanofi-Synthelabo

Dep/Anx

Phase II

KW-6002

Adenosine A2A antag., MAO-B inhibitor

Kyowa Hakko

Parkinson's/Dep

Phase II

OPC-14523

5HT1a agonist/sigma agonist

Otsuka

Depression

Phase II

DOV 216,303

DA/NE/5HT reuptake ihhib.

DOV Pharmaceuticals

Dep/Anx

Phase II

??

DA/NE/5HT reuptake ihhib.

Pfizer

Dep/Anx

Phase II

AR-A000002

5HT1b antagonist

AstraZeneca

Dep/Anx

Phase II

ORG 34167

ion-channel modulator

Organon

Dep/Pain

Phase II

RG2133 (triacetyluridine)

Product of uridine which controls RNA editing

Repligen

Mitochondrial disease/Dep/

Bipolar disorder

Phase I/II

SNEC-2

SCT-11 modulation

Synaptic

Depression

Phase I

GW353162

DA/NE reuptake inhib.

GSK

Dep/Bipolar d/o

Phase I

R-tofisopam

R-isomer of racemic tofisopam (a 2,3-benzodiazepine)

Vela

Anxiety/IBS

Phase I

GW679769

NK-1 antagonist

GSK

Dep/Anx

Phase I

MEM 1414/ R1533/R1500

PDE4 Modulator

Memory Pharm./Roche

AD/Dep

Phase I

DOV 21, 947

DA/NE/5HT reuptake ihhib.

DOV Pharmaceuticals

AD/Dep

Phase I

PRE703

MgluR pro agonist

Prescient

Anxiety

Phase I

100,907

5-HT2A antagonist, NMDA antagonist

Aventis

Insomnia

Phase I

R1204

GPCR modulator

Roche

Depression

Phase I

NGD 96-3

GABA-A agonist

Neurogen

Insomnia

Phase I

SSR149415

V1B antagonist

Sanofi-Synthelabo

Dep/Anxiety/Hyperphagia

Phase I

SB 243213

5HT2c antagonist

GSK

Dep/Anx

Phase I

SNAP-7941

MCH antagonist

Synaptic

Dep/Obesity

Phase I

SB723620

CRF-1 antagonist

GSK

Depression

Phase I

NBI-34041

CRF-1 antagonist

Neurocrine/GSK

Dep/Anx

Phase I

CRF-1 antagonist

CRF-1 antagonist

Janssen

Dep/Anx

Phase I

CRF-1 antagonist

CRF-1 antagonist

Neurogen/Aventis

Dep/Anx

Pre-clinical

CP-448,187

CRF-1 antagonist

Pfizer

Dep/Anx

Pre-clinical

CP-154-526

CRF-1 antagonist

Pfizer

Dep/Anx

Pre-clinical

CRF-1 antagonist

CRF-1 antagonist

Bristol-Myers Squibb

Dep/Anx

Pre-clinical

AZD1134

5HT1b antagonist

AstraZeneca

Dep/Anx

Pre-clinical

R1067

GPCR modulator

Roche

Depression

Pre-clinical

??

PDE4 inhibitor

Memory

Depression

Pre-clinical

MCH antagonist

MCH antagonist

Neurogen

Dep/Obesity

Pre-clinical